Home|||||||Technical Support|

Abeta-pE3 - 218 011

A major component of neuritic plaques in Alzheimer's disease
Monoclonal mouse purified IgG
Cat. No.: 218 011
Amount: 100 µg
Price: $415.00
Cat. No. 218 011 100 µg purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Applications WB: 1 : 1000 (see remarks) gallery  
IP: not tested yet
ICC: not tested yet
IHC: 1 : 400 (see remarks) gallery  
IHC-P/FFPE: 1 : 100 gallery  
ELISA: yes (see remarks)
Clone 2-48
Subtype IgG1 (κ light chain)
Immunogen Synthetic peptide corresponding to AA 3 to 7 from human Abeta-pE3 (UniProt Id: P05067)
Epitop Epitop: AA 3 to 7 from human Abeta-pE3 (UniProt Id: P05067)
Reactivity Reacts with: human (P05067), rat (P08592), mouse (P12023), monkey.
Other species not tested yet.
Specificity Specific for Abeta-pE3.
Remarks

WB: Detects purified Abeta pE3. Complex samples like brain extracts still have to be tested.
Boil membrane after blotting for 3min.
IHC: Antigen retrieval with formic acid is required.
ELISA: The biotinylated antibody (218 011BT) is suitable as detector antibody for sandwich-ELISA with cat. no. 218 111 or 218 511 as capture antibody.

Data sheet 218_011.pdf

References for Abeta-pE3 - 218 011

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.
Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, et al.
Journal of neural transmission (Vienna, Austria : 1996) (2010) 1171: 85-96. 218 011 WB, IHC-P; tested species: human
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.
Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA
Acta neuropathologica (2009) 1184: 487-96. 218 011 WB
Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.
Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth HU, Blennow K, Wirths O, Bayer TA
The Journal of biological chemistry (2012) 28711: 8154-62. 218 011 IP
Porphyromonas gingivalis Infection Induces Amyloid-β Accumulation in Monocytes/Macrophages.
Nie R, Wu Z, Ni J, Zeng F, Yu W, Zhang Y, Kadowaki T, Kashiwazaki H, Teeling JL, Zhou Y
Journal of Alzheimer's disease : JAD (2019) : . 218 011 IHC; tested species: human,mouse
Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice.
Wang X, Wang L, Yu X, Li Y, Liu Z, Zou Y, Zheng Y, He Z, Wu H
International immunopharmacology (2019) 75: 105770. 218 011 IHC; tested species: mouse
Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.
Hartlage-Rübsamen M, Waniek A, Meissner J, Morawski M, Schilling S, Jäger C, Kleinschmidt M, Cynis H, Kehlen A, Arendt T, Demuth HU, et al.
Acta neuropathologica (2015) 1294: 565-83. 218 011 IHC
Identification of thyrotropin-releasing hormone as hippocampal glutaminyl cyclase substrate in neurons and reactive astrocytes.
Waniek A, Hartlage-Rübsamen M, Höfling C, Kehlen A, Schilling S, Demuth HU, Roßner S
Biochimica et biophysica acta (2015) 18521: 146-55. 218 011 IHC
Detection and Quantification of β-Amyloid, Pyroglutamyl Aβ, and Tau in Aged Canines.
Schmidt F, Boltze J, Jäger C, Hofmann S, Willems N, Seeger J, Härtig W, Stolzing A
Journal of neuropathology and experimental neurology (2015) 749: 912-23. 218 011 IHC
Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
Morawski M, Schilling S, Kreuzberger M, Waniek A, Jäger C, Koch B, Cynis H, Kehlen A, Arendt T, Hartlage-Rübsamen M, Demuth HU, et al.
Journal of Alzheimer's disease : JAD (2014) 392: 385-400. 218 011 IHC; tested species: human
The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ.
Kalimo H, Lalowski M, Bogdanovic N, Philipson O, Bird TD, Nochlin D, Schellenberg GD, Brundin R, Olofsson T, Soliymani R, Baumann M, et al.
Acta neuropathologica communications (2013) 1: 60. 218 011 IHC; tested species: human
Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer's disease neuropathology.
Morawski M, Brückner G, Jäger C, Seeger G, Matthews RT, Arendt T
Brain pathology (Zurich, Switzerland) (2012) 224: 547-61. 218 011 IHC; tested species: human
Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
Hartlage-Rübsamen M, Morawski M, Waniek A, Jäger C, Zeitschel U, Koch B, Cynis H, Schilling S, Schliebs R, Demuth HU, Rossner S, et al.
Acta neuropathologica (2011) 1216: 705-19. 218 011 IHC
Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice.
Härtig W, Goldhammer S, Bauer U, Wegner F, Wirths O, Bayer TA, Grosche J
Journal of chemical neuroanatomy (2010) 401: 82-92. 218 011 IHC
Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
Morawski M, Hartlage-Rübsamen M, Jäger C, Waniek A, Schilling S, Schwab C, McGeer PL, Arendt T, Demuth HU, Rossner S
Acta neuropathologica (2010) 1202: 195-207. 218 011 IHC; tested species: human
The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease.
Murray CE, Gami-Patel P, Gkanatsiou E, Brinkmalm G, Portelius E, Wirths O, Heywood W, Blennow K, Ghiso J, Holton JL, Mills K, et al.
Acta neuropathologica communications (2018) 61: 62. 218 011 IHC-P; tested species: human
I716F AβPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-β and α-synucleinopathy with Lewy bodies.
Sieczkowski E, Milenkovic I, Venkataramani V, Giera R, Ströbel T, Höftberger R, Liberski PP, Auff E, Wirths O, Bayer TA, Kovacs GG, et al.
Journal of Alzheimer's disease : JAD (2015) 441: 103-14. 218 011 IHC-P; tested species: human
Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease.
Bayer TA, Wirths O
Acta neuropathologica (2014) 1276: 787-801. 218 011 IHC-P; tested species: human
Oligomeric pyroglutamate amyloid-β is present in microglia and a subfraction of vessels in patients with Alzheimer's disease: implications for immunotherapy.
Wirths O, Hillmann A, Pradier L, Härtig W, Bayer TA
Journal of Alzheimer's disease : JAD (2013) 354: 741-9. 218 011 IHC-P; tested species: human
Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease.
Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O
Neurobiology of aging (2012) 331: 196.e29-40. 218 011 IHC-P; tested species: human
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.
Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, et al.
Journal of neural transmission (Vienna, Austria : 1996) (2010) 1171: 85-96. 218 011 WB, IHC-P; tested species: human
Cat. No.: 218 011
Quantity: 100 µg
Price: $415.00
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.
Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, et al.
Journal of neural transmission (Vienna, Austria : 1996) (2010) 1171: 85-96. 218 011 WB, IHC-P; tested species: human
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model.
Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA
Acta neuropathologica (2009) 1184: 487-96. 218 011 WB
Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.
Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth HU, Blennow K, Wirths O, Bayer TA
The Journal of biological chemistry (2012) 28711: 8154-62. 218 011 IP
Porphyromonas gingivalis Infection Induces Amyloid-β Accumulation in Monocytes/Macrophages.
Nie R, Wu Z, Ni J, Zeng F, Yu W, Zhang Y, Kadowaki T, Kashiwazaki H, Teeling JL, Zhou Y
Journal of Alzheimer's disease : JAD (2019) : . 218 011 IHC; tested species: human,mouse
Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice.
Wang X, Wang L, Yu X, Li Y, Liu Z, Zou Y, Zheng Y, He Z, Wu H
International immunopharmacology (2019) 75: 105770. 218 011 IHC; tested species: mouse
Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.
Hartlage-Rübsamen M, Waniek A, Meissner J, Morawski M, Schilling S, Jäger C, Kleinschmidt M, Cynis H, Kehlen A, Arendt T, Demuth HU, et al.
Acta neuropathologica (2015) 1294: 565-83. 218 011 IHC
Identification of thyrotropin-releasing hormone as hippocampal glutaminyl cyclase substrate in neurons and reactive astrocytes.
Waniek A, Hartlage-Rübsamen M, Höfling C, Kehlen A, Schilling S, Demuth HU, Roßner S
Biochimica et biophysica acta (2015) 18521: 146-55. 218 011 IHC
Detection and Quantification of β-Amyloid, Pyroglutamyl Aβ, and Tau in Aged Canines.
Schmidt F, Boltze J, Jäger C, Hofmann S, Willems N, Seeger J, Härtig W, Stolzing A
Journal of neuropathology and experimental neurology (2015) 749: 912-23. 218 011 IHC
Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.
Morawski M, Schilling S, Kreuzberger M, Waniek A, Jäger C, Koch B, Cynis H, Kehlen A, Arendt T, Hartlage-Rübsamen M, Demuth HU, et al.
Journal of Alzheimer's disease : JAD (2014) 392: 385-400. 218 011 IHC; tested species: human
The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ.
Kalimo H, Lalowski M, Bogdanovic N, Philipson O, Bird TD, Nochlin D, Schellenberg GD, Brundin R, Olofsson T, Soliymani R, Baumann M, et al.
Acta neuropathologica communications (2013) 1: 60. 218 011 IHC; tested species: human
Involvement of perineuronal and perisynaptic extracellular matrix in Alzheimer's disease neuropathology.
Morawski M, Brückner G, Jäger C, Seeger G, Matthews RT, Arendt T
Brain pathology (Zurich, Switzerland) (2012) 224: 547-61. 218 011 IHC; tested species: human
Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.
Hartlage-Rübsamen M, Morawski M, Waniek A, Jäger C, Zeitschel U, Koch B, Cynis H, Schilling S, Schliebs R, Demuth HU, Rossner S, et al.
Acta neuropathologica (2011) 1216: 705-19. 218 011 IHC
Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice.
Härtig W, Goldhammer S, Bauer U, Wegner F, Wirths O, Bayer TA, Grosche J
Journal of chemical neuroanatomy (2010) 401: 82-92. 218 011 IHC
Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.
Morawski M, Hartlage-Rübsamen M, Jäger C, Waniek A, Schilling S, Schwab C, McGeer PL, Arendt T, Demuth HU, Rossner S
Acta neuropathologica (2010) 1202: 195-207. 218 011 IHC; tested species: human
The presubiculum is preserved from neurodegenerative changes in Alzheimer's disease.
Murray CE, Gami-Patel P, Gkanatsiou E, Brinkmalm G, Portelius E, Wirths O, Heywood W, Blennow K, Ghiso J, Holton JL, Mills K, et al.
Acta neuropathologica communications (2018) 61: 62. 218 011 IHC-P; tested species: human
I716F AβPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-β and α-synucleinopathy with Lewy bodies.
Sieczkowski E, Milenkovic I, Venkataramani V, Giera R, Ströbel T, Höftberger R, Liberski PP, Auff E, Wirths O, Bayer TA, Kovacs GG, et al.
Journal of Alzheimer's disease : JAD (2015) 441: 103-14. 218 011 IHC-P; tested species: human
Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease.
Bayer TA, Wirths O
Acta neuropathologica (2014) 1276: 787-801. 218 011 IHC-P; tested species: human
Oligomeric pyroglutamate amyloid-β is present in microglia and a subfraction of vessels in patients with Alzheimer's disease: implications for immunotherapy.
Wirths O, Hillmann A, Pradier L, Härtig W, Bayer TA
Journal of Alzheimer's disease : JAD (2013) 354: 741-9. 218 011 IHC-P; tested species: human
Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease.
Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O
Neurobiology of aging (2012) 331: 196.e29-40. 218 011 IHC-P; tested species: human
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.
Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, et al.
Journal of neural transmission (Vienna, Austria : 1996) (2010) 1171: 85-96. 218 011 WB, IHC-P; tested species: human
Background

Amyloid deposits, also called plaques, of Alzheimer's patients consist of several protein components like the amyloid beta-peptides (Abeta, ) 1-40/42 and additional C- and N-terminally truncated and modified fragments. Very abundant are the isoaspartate (isoAsp)-Abeta and pyroglutamyl (pGlu)-Abeta peptides. The latter are formed by cyclization of the N-terminal glutamate at position 3 or 11 catalyzed by glutaminyl cyclase (QC) resulting in very amyloidogenic and neurotxic variants of Abeta; Abeta-pE3 and Abeta pE11.
In contrast to extracellular plaques that do not perfectly correlate with Alzheimer´s disease intraneuronal Abeta accumulation and vascular Abeta deposits have gained more and more evidence to be among the crucial factors responsible for progressive neuron loss.